News

News 05.06.2020 Schlieren, Switzerland – 4 June 2020 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a COVID-19 immunotherapy. MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent...

News 26.05.2020 Zurich-Schlieren, May 26, 2020. Proteomedix, the Swiss cancer diagnostics company is pleased to announce the appointment of Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD, as Medical Advisor effective June 1, 2020. These accomplished executives bring a wealth of industry expertise to the...

News 19.05.2020 Zurich-Schlieren, Switzerland, May 19, 2020. Proteomedix, the Swiss cancer diagnostics company announces today the publication of the analytical performance results of Proclarix, Proteomedix lead product for improved prostate cancer diagnostics in the peer-reviewed journal PLOS ONE. The report published today highlights the analytical performance of the two CE-IVD assays that measure...

News 15.05.2020 Zurich-Schlieren, Switzerland, May 15, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced the presentation of preclinical data from three of the company’s programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting II, June...

News 12.05.2020 Schlieren-Zurich, CH and Chantilly, VA, USA, May 12, 2020. Proteomedix, the Swiss cancer diagnostics company and Dynex Technologies, announce today a strategic partnership enabling Proteomedix to establish automated workflows for their prostate cancer diagnostics test and sell Dynex instruments to the global clinical market. The partnership builds on the longstanding...